Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: final 5-year analysis of DASFREE: original paper
Patients with chronic myeloid leukaemia in chronic phase (CML-CP) who have a sustained deep molecular response (DMR) are eligible to discontinue treatment and attempt treatment-free remission (TFR). In the DASFREE study (ClinicalTrials.gov; NCT01850004), the 2-year TFR rate after dasatinib discontin...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
September 2023
|
| In: |
British journal of haematology
Year: 2023, Jahrgang: 202, Heft: 5, Pages: 942-952 |
| ISSN: | 1365-2141 |
| DOI: | 10.1111/bjh.18883 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1111/bjh.18883 Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.18883 
|
| Verfasserangaben: | Neil P. Shah, Valentín García-Gutiérrez, Antonio Jiménez-Velasco, Sarah M. Larson, Susanne Saussele, Delphine Rea, François-Xavier Mahon, Moshe Yair Levy, María Teresa Gómez-Casares, Michael J. Mauro, Oumar Sy, Patricia Martin-Regueira, Jeffrey H. Lipton |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1882174402 | ||
| 003 | DE-627 | ||
| 005 | 20240307021820.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bjh.18883 |2 doi | |
| 035 | |a (DE-627)1882174402 | ||
| 035 | |a (DE-599)KXP1882174402 | ||
| 035 | |a (OCoLC)1425200497 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Shah, Neil P. |e VerfasserIn |0 (DE-588)1059838125 |0 (DE-627)798896035 |0 (DE-576)415897084 |4 aut | |
| 245 | 1 | 0 | |a Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response |b final 5-year analysis of DASFREE: original paper |c Neil P. Shah, Valentín García-Gutiérrez, Antonio Jiménez-Velasco, Sarah M. Larson, Susanne Saussele, Delphine Rea, François-Xavier Mahon, Moshe Yair Levy, María Teresa Gómez-Casares, Michael J. Mauro, Oumar Sy, Patricia Martin-Regueira, Jeffrey H. Lipton |
| 264 | 1 | |c September 2023 | |
| 300 | |b Illustrationen | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 29. Mai 2023 | ||
| 500 | |a Gesehen am 29.02.2024 | ||
| 520 | |a Patients with chronic myeloid leukaemia in chronic phase (CML-CP) who have a sustained deep molecular response (DMR) are eligible to discontinue treatment and attempt treatment-free remission (TFR). In the DASFREE study (ClinicalTrials.gov; NCT01850004), the 2-year TFR rate after dasatinib discontinuation was 46%; here we present the 5-year update. Patients with a stable DMR after ≥2 years of dasatinib therapy discontinued treatment and were followed for 5 years. At a minimum follow-up of 60 months, in 84 patients discontinuing dasatinib, the 5-year TFR rate was 44% (n = 37). No relapses occurred after month 39 and all evaluable patients who relapsed and restarted dasatinib (n = 46) regained a major molecular response in a median of 1.9 months. The most common adverse event during the off-treatment period was arthralgia (18%, 15/84); a total of 15 withdrawal events were reported in nine patients (11%). At the 5-year final follow-up, almost half of the patients who discontinued dasatinib after a sustained DMR maintained TFR. All evaluable patients who experienced a relapse quickly regained a DMR after restarting dasatinib, demonstrating that dasatinib discontinuation is a viable and potentially long-term option in patients with CML-CP. The safety profile is consistent with the previous report. | ||
| 650 | 4 | |a chronic phase chronic myeloid leukaemia | |
| 650 | 4 | |a dasatinib | |
| 650 | 4 | |a deep molecular response | |
| 650 | 4 | |a major molecular response | |
| 650 | 4 | |a treatment-free remission | |
| 700 | 1 | |a García-Gutiérrez, Valentín |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jiménez-Velasco, Antonio |e VerfasserIn |4 aut | |
| 700 | 1 | |a Larson, Sarah M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Saußele, Susanne |d 1968- |e VerfasserIn |0 (DE-588)115839860 |0 (DE-627)69162786X |0 (DE-576)29010694X |4 aut | |
| 700 | 1 | |a Rea, Delphine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mahon, François-Xavier |e VerfasserIn |4 aut | |
| 700 | 1 | |a Levy, Moshe Yair |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gómez-Casares, María Teresa |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mauro, Michael J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sy, Oumar |e VerfasserIn |4 aut | |
| 700 | 1 | |a Martin-Regueira, Patricia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lipton, Jeffrey H. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d Oxford [u.a.] : Wiley-Blackwell, 1955 |g 202(2023), 5 vom: Sept., Seite 942-952 |h Online-Ressource |w (DE-627)269758941 |w (DE-600)1475751-5 |w (DE-576)09113997X |x 1365-2141 |7 nnas |a Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response final 5-year analysis of DASFREE: original paper |
| 773 | 1 | 8 | |g volume:202 |g year:2023 |g number:5 |g month:09 |g pages:942-952 |a Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response final 5-year analysis of DASFREE: original paper |
| 856 | 4 | 0 | |u https://doi.org/10.1111/bjh.18883 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.18883 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240229 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 115839860 |a Saußele, Susanne |m 115839860:Saußele, Susanne |d 60000 |d 61200 |e 60000PS115839860 |e 61200PS115839860 |k 0/60000/ |k 1/60000/61200/ |p 5 | ||
| 999 | |a KXP-PPN1882174402 |e 4494126047 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Neil P. Shah, Valentín García-Gutiérrez, Antonio Jiménez-Velasco, Sarah M. Larson, Susanne Saussele, Delphine Rea, François-Xavier Mahon, Moshe Yair Levy, María Teresa Gómez-Casares, Michael J. Mauro, Oumar Sy, Patricia Martin-Regueira, Jeffrey H. Lipton"]},"language":["eng"],"recId":"1882174402","person":[{"display":"Shah, Neil P.","given":"Neil P.","family":"Shah","role":"aut"},{"family":"García-Gutiérrez","role":"aut","given":"Valentín","display":"García-Gutiérrez, Valentín"},{"display":"Jiménez-Velasco, Antonio","given":"Antonio","role":"aut","family":"Jiménez-Velasco"},{"role":"aut","family":"Larson","given":"Sarah M.","display":"Larson, Sarah M."},{"role":"aut","family":"Saußele","display":"Saußele, Susanne","given":"Susanne"},{"role":"aut","family":"Rea","display":"Rea, Delphine","given":"Delphine"},{"family":"Mahon","role":"aut","given":"François-Xavier","display":"Mahon, François-Xavier"},{"role":"aut","family":"Levy","display":"Levy, Moshe Yair","given":"Moshe Yair"},{"display":"Gómez-Casares, María Teresa","given":"María Teresa","family":"Gómez-Casares","role":"aut"},{"display":"Mauro, Michael J.","given":"Michael J.","role":"aut","family":"Mauro"},{"family":"Sy","role":"aut","given":"Oumar","display":"Sy, Oumar"},{"role":"aut","family":"Martin-Regueira","display":"Martin-Regueira, Patricia","given":"Patricia"},{"given":"Jeffrey H.","display":"Lipton, Jeffrey H.","family":"Lipton","role":"aut"}],"note":["Online veröffentlicht: 29. Mai 2023","Gesehen am 29.02.2024"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title_sort":"Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response","subtitle":"final 5-year analysis of DASFREE: original paper","title":"Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response"}],"id":{"doi":["10.1111/bjh.18883"],"eki":["1882174402"]},"physDesc":[{"noteIll":"Illustrationen"}],"relHost":[{"id":{"issn":["1365-2141"],"eki":["269758941"],"zdb":["1475751-5"],"doi":["10.1111/(ISSN)1365-2141"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"British journal of haematology","subtitle":"BJHaem : an official journal of the British Society for Haematology","title":"British journal of haematology"}],"origin":[{"publisherPlace":"Oxford [u.a.] ; Oxford ; Oxford [u.a.]","dateIssuedKey":"1955","dateIssuedDisp":"1955-","publisher":"Wiley-Blackwell ; Blackwell Science ; Blackwell"}],"name":{"displayForm":["ed. R. B. Thompson [u.a.]"]},"recId":"269758941","corporate":[{"role":"isb","display":"British Society for Haematology"},{"display":"European Hematology Association","role":"isb"}],"disp":"Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response final 5-year analysis of DASFREE: original paperBritish journal of haematology","type":{"bibl":"periodical","media":"Online-Ressource"},"titleAlt":[{"title":"the official journal of the British Society of Haematology"},{"title":"BJH ; the official journal of the British Society for Haematology"}],"part":{"text":"202(2023), 5 vom: Sept., Seite 942-952","pages":"942-952","issue":"5","volume":"202","year":"2023"},"language":["eng"],"pubHistory":["1.1955 -"],"note":["Gesehen am 08.05.08"]}],"origin":[{"dateIssuedKey":"2023","dateIssuedDisp":"September 2023"}]} | ||
| SRT | |a SHAHNEILPGTREATMENTF2023 | ||